Analysts think CRMD stock price could increase by 177%
Aug 07, 2024, 6:25 AM
40.49%
What does CRMD do
CorMedix, Inc., based in Berkeley Heights, New Jersey, specializes in developing and commercializing products like DefenCath, a solution to prevent infections in patients with central venous catheters. Founded in 2010, the company employs 40 people and explores taurolidine's potential in treating rare pediatric tumors.
6 analysts think CRMD stock price will increase by 177.04%. The current median analyst target is $11.22 compared to a current stock price of $4.05. The lowest analysts target is $9.09 and the highest analyst target is $19.95.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.